A
AbCellera Biologics D
D
ABCL
12.675
USD
0.31
(2.51%)
Post Trading·12.680USD+0.005(+0.04%)
Last updated: · Delayed 15 min
Volume
339,291
EPS
-1
Div Yield
-
P/E
-23
Market Cap
4,107,300,326
Title: AbCellera Biologics
Sector: Healthcare
Industry: Biotechnology
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.







